Establishment and Fractionation of Metastatic Axillary Lymph Node Cell Suspension for Determination of Protein Expression Levels of Nuclear cFOS and Cytosolic TGFβ1 from Breast Cancer Patients

Vesna Ivanović¹*, Nasta Dedović-Tanić¹, Zorka Milovanović³, Bratislav Stojiljković⁴, Miroslav Demajo¹ and Vesna Mandušić¹

Abstract

**Background:** Metastatic Axillary Lymph Node (mALN) status is currently the most important prognostic factor in the management of primary breast cancer (BC). Thus, development of specimens which enable identification of new mALN markers, involved in the progression of the disease, are of considerable interest. The specific aim of this work was to describe the method of establishment of Metastatic Axillary Nodal Cell Suspension and its fractionation, termed Fractionated Nodal Cell Suspension (FNCS), into nuclear and cytosolic extracts to enable determination of protein expression levels of nuclear cFOS and cytosolic Transforming Growth Factor β1 (TGFβ1) in BC patients.

**Results:** To standardize the procedure, HeLa cells were successfully fractionated into nuclear/cytosolic extracts with confirmed presence of nuclear cFOS and cytosolic TGFβ1 proteins. Subsequently, the ALN Cell Suspension specimens were obtained and further fractionated from a pilot sample of six ALN tissue pairs, mALN versus autologous normal ALN (nALN), dissected from invasive BC patients. The mALN/nALN results revealed overexpression of both nuclear cFOS and cytosolic TGFβ1 protein levels. However, only the TGFβ1 data exhibited statistically significant overexpression, which was proportional to the respective values of mALN diameter of tumor deposits.

**Conclusions:** Detailed protocol for establishment and fractionation of mALN cell suspension specimens, termed FNCS, into nuclear and cytosolic extracts is here described for the first time. This approach might be a convenient ex vivo model for simultaneous analysis of protein, RNA and DNA biomarkers from nuclear/cytosolic extracts of the same mALN tissue sample. It might have potential to enable, in the age of genomics and personalized medicine, an identification of novel mALN biomarkers and thus improve the screening, diagnosis and prognosis of invasive BC.

**Keywords:** Axillary lymph nodes, cFOS, TGFβ1, FNCS, Fractionated Nodal Cell Suspension

*B Correspondence: vesnai@EUnet.rs

1 Department for Radiobiology and Molecular Genetics, Institute of Nuclear Sciences “Vinča”, University of Belgrade, Belgrade 11001, Serbia

Full list of author information is available at the end of the article
lymph nodes (ALN) are the main doorway for tumor cell escape from the primary site to other regions of the body [5]. Consequently, metastatic ALN (mALN) are considered the most important prognostic factors and powerful source of biomolecules that may become reliable metastatic biomarkers. In spite of that, very few studies have been conducted to identify BC biomarkers associated with the ALN metastasis of BC. Therefore, inclusion of new mALN molecular biomarker profiles has been proposed to predict nodal status at the time of BC diagnosis [6].

Considerable research attention has been focussed on a role of deregulation of Transforming Growth Factor β1 (TGFβ1) as tumor promoter step favoring BC invasion and metastasis [7]. Moreover, accumulating evidence shows that FOS transcription factor binding motifs are critical for the regulation of TGFβ1 expression [8]. Thus, cFOS elevation may have utility as a complementary candidate biomarker of BC invasiveness, co-expressed with TGFβ1. Consequently, we have previously proposed that cFOS and TGFβ1 proteins may be considered as a pair of biomarkers of an early assessment of invasive BC [7, 8], providing adequate invasive BC specimens are available. In the past, primary tumor tissue had been fractionated into nuclear [9] or cytosolic [10, 11] extract to assess specific biomarkers of interest. Until recently, however, the protocol for fractionation of mALN nuclear and cytosolic extracts has not been available, presumably due to the specific tough, fibrous nature of mALN tissue.

To date, diameter of tumor deposits and proliferation index Ki67 [6, 12, 13] are the most prominent clinically used features of mALN. Both parameters are detected by routine histology [14] involving the tissue paraffin blocks of 4-μm slices for each node [15, 16] and their staining with either Haematoxylin and Eosin (H&E) or Immunohistochemistry (IHC), respectively [17]. Although indispensable, the histology methodology imposes some limitations [16]. Namely, in a significant portion of cases, due to clustered spacial distribution of tumor cells within a lymph node, the histology sectioning generates sampling errors leading to false negative mALN sections [18]. Consequently, the pool of biomarkers in various slices may be different. To overcome this problem, Edwards and co-workers [19] introduced mALN Cell Suspension as new specimens thereby covering the whole content of entire mALN. Based on this mALN specimen source, we developed the method, termed Fractionation of Nodal Cell Suspension (FNCS), which includes the mALN Cell Suspension approach and its fractionation into nuclear and cytosolic extracts to be suitable for determination of protein expression levels of respective native proteins. Using this experimental design, we have previously observed overexpression of TGFβ1 protein in cytosolic extracts of mALN [7]. Likewise, we encountered a case of an advanced Triple Negative Breast Cancer (TNBC) patient with overexpressed both cytosolic TGFβ1 and nuclear cFOS proteins as a pair of mALN biomarkers for an early assessment of TNBC poor prognosis [8]. However, in above mentioned studies [7, 8], apart from the outlined methods used, specific experimental protocols were not described. Having in mind that the FNCS design might help to generate an important predictive tool suitable for comparative analysis of individual patients in present era of genomics and personalized medicine [2], we undertook the present study. The main goal was to describe the full methodology of establishment and fractionation of mALN Cell Suspension thus providing FNCS specimens of nuclear and cytosolic extracts and determination of protein expression levels of respective cFOS and TGFβ1.

The workflow of the this study is presented in Fig. 1. After extirpation of the entire axillary lymph node of BC patient and selection of the pertinent nodes (mALN/nALN pairs), the following steps, included in the experimental design, were: i) mechanical disaggregation of ALN, chopped and filtered through 100μm sieve devices, to obtain mALN cell suspension free from fat and connective tissue (mALN Cell Suspension); ii) model protocol of HeLa cell fractionation into nuclear and cytosolic extracts, confirmed by respective internal controls, to be implemented on mALN Cell Suspension to obtain FNCS specimens and generate nuclear/cytosolic extracts; iii) determination of protein expression level of nuclear cFOS and cytosolic TGFβ1 by ELISA; iv) correlation of the respective cFOS and TGFβ1 biomarker levels with mALN diameter of tumor deposits for each BC patient.

Since mALN tissue sample is heterogeneous in terms of its cell content (including: various BC malignant clones, fibroblasts, macrophages, lymphocytes etc.) this protocol enables the use of autologous normal ALN (nALN) of each patient as an optimal choice of negative control. Taken together, this study provides tools to researchers termed FNCS, in which mALN and nALN tissue samples are used as initial ex vivo materials, to follow the protocol “from tough mALN/nALN tissue, through mALN/nALN Cell Suspension, to fractionate the nuclear/cytosolic extracts” and enable ELISA determination of respective protein biomolecules. The method provides considerable advantages, when compared to current pathohistological BC diagnostics which is, during routine examination, rather limited to defined slices which cannot cover the complete volume of the nodal tissue.
Results

Hela Cell In Vitro Model for Fractionation of Nuclear and Cytosolic Extracts and Determination of Respective Protein Expression Levels of cFOS and TGFβ1

In order to save the precious ALN tissue, the experimental approach included the use of HeLa cell culture to confirm the fractionation protocol described in Methods. Historically, HeLa cell fractionation into nuclear and cytosolic fractions had been introduced in molecular biology research about four decades ago [20]. Moreover, previous studies have established that transcription factors including cFOS are nuclear markers of mammalian cells as demonstrated in HeLa cell nuclear extracts [21]. Likewise, the HeLa cell cytoplasmic extracts have been used to study cytoplasmic proteins [22]. Based on these facts we have monitored the time courses of serum-induced nuclear cFOS and cytosolic TGFβ1 proteins. The results, presented in Fig. 2 reveal that nuclear cFOS reached and kept the plateau values between 4 and 6 hours after serum treatment (Fig. 2A). Accordingly, as recommended by the manufacturer [21], the 4 hr. nuclear extract point was used as cFOS positive control sample in subsequent ALN measurements of cFOS. To verify the usefulness of the selected fractionation protocol on cytosolic TGF-β1 detectability, autologous time points of HeLa cytosolic extracts were analyzed by TGF-β1

---

Fig. 1 Workflow of the experimental design for the present study, to establish and fractionate Metastatic Nodal Cell Suspension specimen termed FNCS, which enables determination of protein expression level of nuclear cFOS and cytosolic TGFβ1
ELISA. The results in Fig. 2B illustrate that the cytosolic TGF-β1 was induced rapidly and reached maximal value at 2 hours after serum treatment, followed by continuous decrease in values. To verify whether the detected cFOS and TGF-β1 were derived from HeLa cell nucleus and cytoplasm, respectively, we performed the following experiment. The nuclear (N) and cytosolic (C) fraction of the two time points (t = 2 and t = 4 hrs) in Fig. 2 have been analyzed for the presence of either cFOS in cytosolic extracts, or TGF-β1 in nuclear extracts. The data presented in Fig. 3 reveal that neither was cFOS detected in cytosolic extracts, nor was TGF-β1 detected in nuclear extracts of HeLa cells (Fig. 3). Taken together, these results indicate that the selected fractionation protocol has successfully separated cytosolic from nuclear fraction of HeLa cells and preserved the native nature of the analyzed proteins.

**Description of ALN Tissue Morphology**

These findings encouraged us to morphologically characterize mALN tissue of pilot samples of six patients with clinical characteristics of invasive BC. These patients, labeled 1-6, were described in Table 1. In addition, respective normal ALN (nALN) tissue was selected from each patient as an optimal choice of negative control tissue. Subsequent H&E staining was performed on pairs of surgical tissue for each patient. Figure 4 illustrates cell morphology of ALN tissue pairs for patient #1 in Table 1. The results for control nALN, reveal stasis, multifocal lipomatosis and sinus histiocytosis of the lymph node without metastatic deposits (Fig. 4A). On the other hand, in case of mALN (Fig. 4B) the morphology reveals large malignant polygonal cells with eosinophilic cytoplasm and hyperchromatic nuclei. These cytology features correspond to primary breast cancer.

**Individualized Comparative Analysis of Diameter of Tumor Deposits Versus Respective ALN Nuclear cFOS and Cytosolic TGF-β1 Levels**

The individualized diameter of tumor deposits (range: 80-1.8 mm, median value: 13.5 mm) assessed from the H&E staining of formalin-fixed, paraffin-embedded slices, are presented in Fig. 5A and Table 2. However, H&E staining does not always provide enough contrast to differentiate all tissues and cellular structures [24], therefore in these cases more specific stains by IHC method are used. Likewise, quantifying the IHC stains is also limited, subject to human error, and not standardized worldwide [25]. Due to these disadvantages, the protocol of FNCS method was implemented on pairs of ALN tissues from patients 1-6 in Table 1 as described in Methods. The quantitative parameters obtained from these experimental procedures are summarized in Table 2.

For each patient labeled consecutively 1-6, they include: the initial tissue weight (range: 790-190 mg), total viable cell number (range: 18.6-3.6 \times 10^6), yields of total nuclear protein (range: 3.2-0.6 mg) and total cytosolic protein (range: 6.5-0.9 mg) of the metastatic ALN. Respective measurements of normal ALN values of the same parameters revealed similar ranges and yields as described in Table 2. (data not shown).

The levels of cFOS and TGFβ1 expression in the mALN/nALN tissue pairs of respective FNCS specimens are presented in Fig. 5B & C and Table 2. The data in Fig. 5B indicate that cFOS levels in mALN nuclear extracts (median value:13.20, n = 3) were elevated when compared with those of nALN (median value: 2.81%, n = 6), although statistical significance (p > 0.05) was not observed. On the other hand, the data in Fig. 5C...
Fig. 3 Test of internal control: to verify that the detected cFOS and TGFβ1 markers were derived from HeLa cell nucleus and cytoplasm, respectively. Histograms represent the two time points (t = 2 & t = 4 hrs) selected from time curves presented in Fig. 2 and the two markers measured in nuclear extracts (designated as N2 & N4) and cytosolic extracts (designated as C2 & C4): A cFOS oncoprotein levels in nuclear versus cytosolic HeLa cell extracts and B TGF-β1 levels in nuclear versus cytosolic HeLa cell extracts.

Table 1 Clinical and pathohistological characteristics of BC patients from whom metastatic ALNs were dissected

| Characteristics | Patients’ number | 1 | 2 | 3 | 4 | 5 | 6 |
|----------------|-----------------|---|---|---|---|---|---|
| Age at surgery | Post menopausal status | 74 | 39 | 70 | 52 | 48 | 66 |
| ER | PR | 0 | 0 | 8 | 8 | 7 | 8 |
| HER2 | 0 | 0 | 1 | 0 | 1 | 1 |
| TNBC status | 0 | 0 | 0 | 8 | 8 | 8 |
| Histological Grade | 0 | 0 | 0 | 8 | 8 | 8 |
| Type AJCC | 0 | 0 | 0 | 8 | 8 | 8 |
| Clinical Stage | 0 | 0 | 0 | 8 | 8 | 8 |
| Lymph node status | 3/8 | 4/18, pni+ | 7/13, pni+ | 7/14 | 1/8, pni+ | 1/15 |
| pTNM | pt4d, N2, M0 | pt1a, N2a, M0 | pt2, N2a, M0 | pt1c, N1a, M0 | pt1c, N1a, M0 |

Notes:

- Grading scale used to evaluate ER and PR ranged from 0 to 8. The cut-off value was 3, above which the markers were considered positive as proposed previously.
- Assessment of histological grade of primary breast tumor was based on Scarff-Bloom-Richardson system (I-III).
- Patients were staged according to the American Joint Committee on Cancer (AJCC) 6th edition staging manual.
- Metastasis observed in 3 out of 8 ALNs.
- Large primary tumor, ‘d’, with malignant infiltration of surrounding skin.
- pni+, malignant infiltration of perinodal adipose tissue.
- TU1 and TU2 signify two primary tumor lesions diagnosed simultaneously on the same breast of the indicated BC patient.
show that TGF β1 levels in mALN cytoplasmic extracts (median value: 1.05 ng/mg protein, n = 6) were significantly (p < 0.05) elevated when compared with those of nALN cytoplasmic extract (median value: 0.48 ng/mg protein, n = 6) which was proportional to the size of respective mALN tumor deposits (Table 2). As a consequence, they suggest that TGF β1 overexpression is associated with the presence of metastatic cells in the ALN-positive tissue specimens. Moreover, Fig. 5A and C illustrate complementary role of routine histology and FNCS analysis in confirmation of TGF β1 as an individual putative metastatic biomarker, suggesting that both methods are beneficial in diagnostics of invasive BC patients.

**Discussion**

It is now well established that accurate staging of the ALN for metastatic disease is critical in deciding the appropriate management of BC patients. Metastasis to the axillary nodes is the earliest sign of the BC metastatic spread and this process occurs at a higher rate than any single distant organ metastasis [26]. However, probability of
false negatives due to the routine ALN histology sectioning underestimates ALN positivity in a significant proportion of cases (for details see Introduction). Likewise, pathologists face difficulties in detecting ALN micrometastasis. In these cases they use IHC staining and multiple sectioning of each node which is time consuming and expensive [19]. With these justifications, in the present study we described in details the establishment and fractionation protocol of mALN cell suspension into nuclear and cytosolic extract, termed Fractionated Nodal Cell Suspension (FNCS) as bench flow procedure to investigate invasive BC biomarkers and possibly assess the ALN status as the subsidiary tool in routine clinical use.

Currently, available model systems for pre-clinical metastatic BC research, include primary cell culture, immortalized cell lines, mouse xenografts [27] and organoid technology [28, 29]. Although essential for discovery, development, and testing of new therapies, these models have both advantages and disadvantages [17]. In spite of that, very few studies have been conducted to identify BC biomarkers associated with the ALN metastasis of BC. Among these, mammoglobin has been identified for the detection of metastatic ALN in BC [30], as detected by absolute quantitative real-time reverse transcription-PCR (qRT-PCR). Therefore, inclusion of additional new mALN molecular biomarker profiles is needed to predict nodal status at the time of BC diagnosis [6].

Here we describe the design of a potentially new BC specimen, termed Fractionated Nodal Cell Suspension to establish and fractionate mALN Cell Suspension based on disaggregation of dissected mALN tumor tissue, preparation of mALN Cell Suspension, its further fractionation and determination of protein expression level of nuclear cFOS and cytosolic TGFβ1 from the same ALN sample. Although cFOS is elevated but not statistically significant, our TGFβ1 results reveal statistically significant overexpression in respective cytosolic extracts, which was proportional to the size of respective mALN tumor deposits. Major limitation of this data pertains to the small sample size. Nevertheless, our findings imply that the TGFβ1 overexpression is associated with the presence of metastatic BC cells. Large scale studies, however, are necessary to confirm the conclusion.

Taken together, the FNCS method may facilitate simultaneous comparative analysis of other protein, RNA and DNA biomarkers from the same ALN tissue sample. This might provide very powerful measurements which allow direct genotypic and phenotyping correlations [26]. Along this line, the main characteristics of cells in FNCS, such as the expression of ER, PR and HER2, may be analyzed to presumably generate surrogate ALN samples to explore whether they match the histopathologic characteristics of the corresponding BC patients. Alternatively, we expect advanced application of the FNCS model system which might include an enrichment of a particular malignant clone content starting with mALN Cell Suspension specimen and clonal evolution during the migration e.i. metastasis. Namely, mALN Cell Suspension specimens being heterogeneous in the cell population (for details see Introduction) could be further separated by selective gradient to obtain individual cell types [17] to be further sorted out [31] by Fluorescence Activated Cell Sorter (FACS). After these steps, samples of homogeneous tumor cell clones are to be obtained. The proposed FNCS design might be advantageous, when compared to highly sophisticated and expensive Laser Capture

---

Table 2 Individual parameter values measured in the selected single metastatic ALN (mALN) for each of the BC patient presented in Table 1 and described in Methods and Fig. 4

| Parameter                                      | Patients’ number |
|-----------------------------------------------|-----------------|
| Diameter of tumor deposits (mm)               | 1 2 3 4 5 6     |
| % of malignant cells                          | 80% 100% 100% 100% 30% n.a. |
| Presence of micrometastasis                   | none none none none positive n.a. |
| Initial tissue weight (mg)                    | 790 720 190 660 630 530 |
| Total viable cell number (x 10^-5)            | 18.6 3.6 5.2 9.0 3.8 3.9 |
| Nuclear protein yield (mg)                    | 3.2 0.6 1.0 1.7 1.1 0.8 |
| Cytosolic protein yield (mg)                   | 6.5 1.2 1.7 2.5 0.9 1.2 |
| cFOS level (%)                                | 15.50 8.75 13.20 0.00 0.00 0.00 |
| TGFβ1 level (ng/mg protein)                   | 3.60 1.20 0.90 1.02 0.67 1.08 |

*The size of tumor deposits was assessed from the H&E slices of formalin-fixed, paraffin-embedded ALN tissue

*mALN1* essentially exhibited the conglomerate size: 80 x 50 x 40 mm, with malignant infiltration of surrounding ALN tissue

observed morphologically

*not available due to much too small ALN size and the entire "mALN 6" was used for cFOS and TGFβ1 analysis

---
Microdissection (LCM) which is based on the small number of cells consequently yielding low RNA and DNA amounts. Furthermore, described FNCS design provides an excellent sample source for investigating molecular changes during the disease progression.

**Conclusion**

Our study provides, for the first time, detailed description of the experimental method for establishment and fractionation of Metastatic Axillary Nodal Cell Suspension into nuclear and cytosolic extracts, termed FNCS, for determination of protein expression levels of respective cFOS and TGFβ1. This convenient procedure might be a valuable tool in pre-clinical research of other invasive BC biomarkers. It has considerable advantages, when compared to pathohistological ALN diagnostics, since one need not worry about false negatives and one can reliably quantify treatment-dependent comparative biomarker levels of individual patients. Thus, in the present era of genomics and personalized medicine, the described FNCS method might facilitate the identification of new mALN biomarkers and improve the screening, diagnosis and prognosis of invasive BC.

**Methods**

**Patients and ALN Assessment**

Twelve consecutive female BC patients, attending the hospitals within 6 weeks (from August 24, to October 04, 2007), underwent extirpation of the entire axillary region. Out of this fresh tissue, 12-15 nodes per patient have been screened histopathologically and the study cohort of 6 ALN-positive patients was obtained and presented in Table 1. None of these patients were previously treated. The proposed prospective study had received the Institutional Review Board approval and a written informed consent was obtained from each woman according to the National Health Regulation. For each BC patient, a fresh tissue of single metastatic ALN with maximal size of tumor deposits was divided in half. The first half underwent routine histopathological examination using cryotome-cut frozen sections stained by H&E. After confirmation of the presence of metastatic deposits, the second half of fresh tissue, selected for this research, was immediately snap-frozen and stored at −70°C, within the shelf time of 2 months. Simultaneously with mALN, autologous, histopathologically verified, normal ALN control (nALN) was collected. These pairs of tissue samples, after defrosting, were subjected to disaggregation protocol (see below) to establish respective ALN Cell Suspensions and further fractionation to obtain FNCS specimens for subsequent cFOS and TGFβ1 determination.

**Protocol for Disaggregation of mALN Tissue and Establishment of mALN Cell Suspension Specimen**

Previous mechanical disaggregation procedures of ALN tissue involved chopping with scalpel blade and multiple injections [19], use of rotating knives [15] and filtering through 100μm cell strainer [16]. In our study, frozen ALN tissue specimens were processed for fractionation on ice in the following manner:

**a.** The ALN tissue samples were quickly thawed, the weight measured and then chopped with scalpel in a small glass petri dish; **b.** The pieces of ALN tissue were resuspended with PBS (4×1 mL) and simultaneously transferred on an INOX 18/10 sieve (mesh size 100×100 μm, net diameter ø 20 mm) obtained from Fasil A.D. Arilje, Serbia, (www.fasil.co.rs) which is placed above a new petri dish (Fig. 6); **c.** Macerated tissue was pulverized on the sieve surface with rubber piston to separate fat and connective tissue from intact cells which are filtered through a mesh into a petri dish; **d.** The cell suspension was then transferred into an Ependorf tube, centrifuged (850 g, 15 min, 4°C), and the cell pellet packed volume (V_{pack}) estimated; **e.** The supernatant was decanted and the obtained cell pellet diluted with 5×V_{pack} of ice-cold hypotonic lysis buffer and processed as described below (see Section Protocol for fractionation of HeLa cells...); **f.** An aliquot (50 μL) of a pooled cell pellet was taken for viable cell counting with hemocytometer (Neubauer chamber) by Trypan blue exclusion. Further steps of fractionation of mALN cell suspension were identical as performed for HeLa cells (see below under: Steps 1-11)

**Hela Cells**

HeLa cells were grown in RPMI 1640 medium supplemented with 10% Fetal Calf Serum (serum) in the CO2
incubator. For the time course experiment, 6 medium T flasks (dimensions: 75 cm²) were grown until 80-90% confluence. Then cell monolayers, in all flasks, were washed with PBS followed by addition of serum free RPMI which was left to incubate with the cells for 12 hour. At the time point “zero”, a moment after a 12-hour incubation ended, serum free RPMI was replaced by the working medium (RPMI plus 10% FCS) to initiate serum-treatment. Cell suspension from the “zero” flask was fractionated immediately and successive fractionations followed at the incubation time points of 2, 4, 5, 6 and 7 hours.

Protocol for Fractionation of HeLa Cells and/or mALN Cell Suspension

Fractionation into nuclear and cytosolic extracts of HeLa cells and/or mALN Cell Suspension was prepared by the modifications of the protocols of Prusty et al. [9] and Riol et al. [32]. Considering the facts that the quoted references were used on primary tumor tissue and lymphocytes, respectively, we here describe the full fractionation protocol, adopted from Chemicon Inc. [21], which was used in this study:

1. After trypinization of the HeLa cell monolayer and determination of the cell pellet packed volume (Vpack), the cell pellet was resuspended in 5xVpack of ice-cold hypotonic lyses buffer (see below under Extraction Solutions); 2. For the purpose of cell swelling, the lysate was incubated on ice for 15 min, centrifuged at 850 g for 15 min at 4 °C, and supernatant discarded; 3. The cell pellet, from multiple ependorf tubes was again resuspended in 5xVpack of ice-cold hypotonic lyses buffer and homogenized by drawing and ejecting the cell suspension content with a syringe/No 27 gauge needle; 5. Homogenate was centrifuged at 8,000 g for 20 min at 4 °C, and supernatant saved (containing cytosolic extract) and an aliquot (50 μL) was used to measure total cytosolic protein; 6. Remaining cytosolic extract was immediately aliquoted, snap frozen with liquid nitrogen and stored at −70 °C for cFOS determination.

Solutions and Reagents

Fractionation of both HeLa cells and ALN cell suspensions included the use of following buffers: A. Hypotonic cell lysis buffer: 10 mM HEPES pH 7.9, 1.5 mM MgCl₂, 10 mM KCl, 2.5 mM DTT, 0.1% Triton X-100, plus PKIC (Protein Kinase Inhibitor Cocktail); and B. Nuclear extraction buffer: 20 mM HEPES pH 7.9, 1.5 mM MgCl₂, 420 mM NaCl, 0.2 mM EDTA, 2.5 mM DTT, 1% Igepal CA-630, 25% (v/v) glycerol plus PKIC. In order to reduce proteolysis, dephosphorylation and denaturation of proteins, related inhibitors were added into the lysing buffers prepared as stock solutions of inhibitor cocktails: I. 50 x PIC (Protease Inhibitor Cocktail) in ethanol as solvent containing: 0.5 mg/mL leupeptin; 0.5 mg/mL pepstatin; 0.8 mg/mL benzamidine hydrochloridehydrate; and 0.1 M PMSF. The stock was aliquoted in 50μL aliquots and kept at −20°C. II. 100 x KIC (Kinase Inhibitor Cocktail) in water as solvent, contained: 0.5 M sodium fluoride (NaF); and 0.1 M sodium orthovanadate. The stock was aliquoted in 60 μL aliquots and kept at −20°C. III. 40 x DTT (0.1 M DTT solution is used to reduce disulphide bridges in proteins. The stock was aliquoted in 100 μL aliquots and kept at −20°C.

Determination of Protein Yields and cFOS / TGF-β1 Protein Levels

Protein determination of nuclear and cytosolic protein yields (presented in Table 2) was performed in microplates by a micro Lowry assay [33] with the absorbance read at 650 nm (Bio Tek Instruments, Inc., Winooski, Vermont, USA). Final concentration of total proteins for both cytoplasmic and nuclear ALN tissue extracts covered the range from 3.2-9.9 mg/mL. However, the optimal total protein concentration of 2 mg/mL for TGF-β1 and 3 mg/mL for cFOS was used for comparative analysis within the single plate/assay (Fig. 5). The level of cFOS protein was determined by the Transcription Factor Assay Colorimetric kit according to the manufacturer’s instructions [21]. The results are presented as percentage of the absorbance at 450 nm compared to simultaneously analyzed cFOS positive control (4 hr. time point of serum treated HeLa nuclear extracts) considered as 100%. The TGF-β1 protein concentration was determined as described before [7]. The immunoreactive TGF-β1, obtained by acid-activation of latent TGF-β1, was analyzed by the Quantikine TGF-β1 ELISA kit according to the manufacturer’s protocol for the cell culture/Urine with RD1-21 diluting agent/ dilution factor: 14-24. (R&D Systems Inc. Minneapolis, MN, USA). Taken together, ELISA spectrophotometric analysis for
the measurements of cFOS and TGF-β1, with the absorbances at 450 nm and 650 nm, was performed on the Microplate ELISA reader Wallac 1420 (PerkinElmer, Inc., Waltham, Massachusetts, USA). The cFOS / TGF-β1 levels in ALN extracts are presented in Table 2 and Fig. 5.

Statistics
For statistical analysis, the Stat Soft (Hamburg, Germany) statistical package was used. The median values and one-tailed test were used, for ALN tissue extracts measurements, since the number of ALN samples was small [34]. The significance levels between the medians for the subgroup distributions of cFOS and TGFβ1 points in control versus metastatic nuclear and cytosolic ALN tissue extracts, respectively was calculated via the Chi-square, one-tailed test. Level of significance for statistical tests was set at p < 0.05. All experimental points in Figs. 2, 3, 5B and C were performed in duplicates. The variation between the duplicates in a single assay did not exceed 20%. The coefficients of variation (CV) for the cFOS and TGF β1 groups ranged from 22.74 to 70.21%.

Abbreviations
BC: Breast Cancer; ALN: Axillary Lymph Nodes; mALN: Metastatic Axillary Lymph Nodes; nALN: Normal Axillary Lymph Nodes; FNCS: Fractionated Nodal Cell Suspension; TGFβ1: Transforming Growth Factor β1; H&E: Haematoxylin and Eosin staining; IHC: Immunohistochemistry; TNBC: Triple Negative Breast Cancer; FCS:serum: Fetal Calf Serum; PKIC: Protein Kinase Inhibitor Cocktail.

Acknowledgements
The authors wish to thank Mr. Branislav Djurasevic for skillful literature search.

Authors’ Contributions
ZM and BS selected, processed and performed the histological examination of surgical ALN tissue, VI and NDT developed and processed FNCS specimens including subsequent ELISA determinations. VM performed HeLa cell standardization experiments and analyzed all the data. MD performed the statistics and wrote the first draft of the manuscript. All authors participated in the final draft writing, read and approved the final manuscript.

Funding
Financial support for this work, under Research Theme “Molecular alterations as prognostic and predictive markers in human malignant tumors” - 0802103 (VM, Principal Investigator), was provided by the Ministry of Education, Science and Technological Development, Republic of Serbia (Registration number: 451-03-9/2021-14/200017). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the manuscript, apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Availability of Data and Materials
Not applicable.

Declarations
Ethics Approval and Consent to Participate
Surgical sample collection has been approved by the Independent Ethical committees of both the Institute of Oncology and Radiology of Serbia, and Oncology Institute of Vojvodina, Sremskas Kamenica, Serbia. Before sample collection, all patients have signed an informed consent to authorize all the procedures.

Consent for Publication
Not applicable.

Competing Interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1 Department for Radiobiology and Molecular Genetics, Institute of Nuclear Sciences “Vinča”, University of Belgrade, Belgrade 11001, Serbia. 2 State University of Novi Pazar, Department of Natural Sciences and Mathematics, Novi Pazar, Serbia. 3 Institute of Oncology and Radiology of Serbia, Belgrade, Serbia. 4 Oncology Institute of Vojvodina, Sremskas Kamenica, Serbia.

Received: 25 October 2021   Accepted: 2 May 2022
Published online: 04 June 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Aleksandaranya MA, Vandenbergheb ME, Marchiòc C, Ellia IO, Sapino A, Rakha EA. Tumour heterogeneity of breast Cancer: from morphology to personalized medicine. Pathobiology. 2018;85:23–34.
3. Ellsworth RE, Blackburn HL, Shriver CD, Soon. Shingon P. Ellsworth DL. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;63:65–72.
4. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast Cancer Organoids captures disease heterogeneity. Cell. 2018;172:373–86.
5. Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22:226–33.
6. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O. Ki‑67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol. 2013;44:39–46.
7. Ivanović V, Dedović‑Tanić N, Milovanović Z, Lukić S, Nikolić S, Baltic V, et al. Quantification of transforming growth factor beta 1 levels in metastatic axillary lymph node tissue extracts from breast cancer patients: a new specimen source. Anal Quant Cytol Histol. 2009;31:288–95.
8. Ivanović V, Dedović‑Tanić N, Milovanović Z, Lukić S, Nikolić S, Baltic V, et al. Case with triple negative breast cancer shows overexpression of both cFOS and TGF‑β1 in node‑positive tissue extracts. Perinat Med. 2016;13:523–30.
9. Prusty BK, Das BC. Constitutive activation of transcription factor AP‑1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP‑1 activity in HeLa cells by curcumin. Int J Cancer. 2005;113:951–60.
10. Romain S, Formento JL, Guirou O, Francoual M, Milan G, Marti M. Determination of oestrogen receptors by enzyme immunoassay: Technical differences between laboratories and their consequences. Eur J Cancer. 1994;30:740–6.
11. Ferrero J‑M, Ramaiali A, Formento J‑L, Francoual M, Etienne M‑C, Peyrottes I, et al. p53 determination alongside classical prognostic factors in node‑negative breast cancer: an evaluation at more than 10‑year follow‑up. Ann Oncol. 2000;11:399–7.
12. Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE. Breast Cancer metastasis to axillary lymph nodes: are changes to the lymph node “soil” localized or systemic? Breast Cancer. 2017;11:1–5.
13. Sun X, Kaufman PD. Ki‑67: more than a proliferation marker. Chromosoma. 2018;127:175–86.
14. Nasser IA, Lee AKCS, Bosari S, Saganich RS, Hartley G, Silverman ML. Occult axillary lymph node metastases in “node‑negative” breast carcinoma. Hum Pathol. 1993;24:950–7.
15. Ulmer A, Fiher Jr, Schanz S, Sotlar K, Breuning H, et al. Detection of melanoma cells displaying multiple genomic changes in Histopathologically negative sentinel lymph nodes. Clin Cancer Res. 2005;11:5425–32.

16. Weidele K, Stojanovic N, Feltner G, Markiewicz A, Schreiter S, Albertr B, et al. Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples. Int J Cancer. 2019;145:232–41.

17. Gilbert-Ramos A, Lopez C, Bosch R, Fontoura L, Bueno G, Garcia-Rojo M, et al. Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view. Histochem Cell Biol. 2019;152:177–93.

18. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet. 1999;354:896–900.

19. Edwards M, Twin J, Wilkinson S. New technique to assess the axilla for breast cancer metastases using cell separation technology. ANZ J Surg. 2002;72:655–9.

20. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475–89.

21. Chemicon International Inc, Manual for Jur/Fos Transcription Factor Assay Colorimetric: HeLa cell Cytosolic and Nuclear Extraction Procedure. 2007. pp. 5–7. www.chemicon.com. Accessed 9 Aug 2007.

22. Mayeda A, Kraner AR. Preparation of Hela cell nuclear and cytosolic S100 extracts for in vitro splicing. In: Haynes SR, editor. RNA-protein interaction protocols. Valley Stream: Humana Press. Methods Mol Biol. 1999;118:309–14. https://doi.org/10.1385/1-59259-676-2:309.

23. Greene FL, Page DL, Fleming ID. Cancer staging manual. 6th ed. New York: Springer; 2002. p. 221–40.

24. Schulte EK. Standardization of biological dyes and stains: pitfalls and possibilities. Histochemistry. 1991;95:319–28.

25. Advantages and disadvantages of immunohistochemistry. Available at https://www.dermnetnz.org/topics/immunohistochemistry-stains/. Accessed 9 May 2021.

26. Bakkaean B, Gholamin M, Tabatabaee Yazdi SA, Forghani MN. Novel biomarkers aim at detecting metastatic sentinel lymph nodes in breast cancer. Iran Biomed J. 2020;24:183–91.

27. DeRose YS, Gilgorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, et al. Patient derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol. 2013;14(23):1–43.

28. Mazzucchelli S, Piccotti F, Allevi R, Truffi M, Sorrentino L, Russo L, et al. Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer. Biol Proced. 2019; Available at: https://doi.org/10.1186/s12575-019-0099-8. Accessed 12 June 2021.

29. Clevers H, Tuverston DA. Organoid model for Cancer research. Ann Rev Cancer Biol. 2019;3:223–34.

30. Monsalve-Lancheros A, Ibáñez-Pinilla M, Ramírez-Cavijos S. 2018 detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: a systematic review and meta-analysis. PLoS One. 2019; Available at: https://doi.org/10.1371/journal.pone.0216989. pdf. Accessed 23 June 2021.

31. Joksić G, Filipović-Tričković J, Mičić M, Joksić I, Valenta Šobot A, Demajo M. Optimization of the method for isolation of epithelial cells from the non-glandular part of the rat stomach for flow cytometry. Vet Archiv. 2020;90:517–25.

32. Riol HA, Jeune B, Moskovic A, Bathum L, Wang E. Optimized lymphocyte protein extraction performed simultaneously with DNA and RNA isolation: application to the study of factors affecting DNA, RNA, and protein recovery from lymphocytes of the oldest individuals. Anal Biochem. 1999;275:192–201.

33. Determination of Total Protein by the Lowry Method Using the BioTek Instruments ELx808 Microplate Reader. https://www.biotek.com/resources/docs/ELx808_Determining_Total_Protein_Lowry_Method.pdf. Accessed 2 Sept 2021.

34. Sokal RR, Rohlf JF. Introduction to biostatistics. 2nd ed. San Francisco: WH Freeman and Company; 1973.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions